Page 216 - Read Online

Giakoustidis et al. Sorafenib-everolimus for metastases after liver-transplantation

Patient consent
The patient has provided us an informed written
consent, available upon request.

Ethics approval
An ethics approval is not necessary for a case report;
the informed written consent is sufficient.

REFERENCES

1. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing
increase in the incidence of hepatocellular carcinoma in the United
States: an update. Ann Intern Med 2003;139:817-23.
2. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti
F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver
transplantation for the treatment of small hepatocellular carcinomas
in patients with cirrhosis. N Engl J Med 1996;334:693-9.
3. European Association for Study of Liver; European Organisation for
Research and Treatment of Cancer. EASL-EORTC clinical practice
guidelines: management of hepatocellular carcinoma. Eur J Cancer
2012;48:599-641.
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de
Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta
C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath
Figure 3: Recent 18-FDG-PET/CT (Volume rendering) showing no I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D,
lesions in ribs or spine. FDG: fluorodeoxyglucose; PET: position Bruix J; SHARP Investigators Study Group. Sorafenib in advanced
emission tomography; CT: computed tomography hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
5. De’Angelis N, Landi F, Carra MC, Azoulay D. Managements of
Literature search: D. Giakoustidis, A.A. Gargavanis, recurrent hepatocellular carcinoma after liver transplantation: a
N. Salveridis, E. Cholongitas, E. Sinakos, K. systematic review. World J Gastroenterol 2015;21:11185-98.
Papapolychroniadis, V. Papanikolaou 6. Toso C, Mentha G, Majno P. Integrating sorafenib into an algorithm
Data acquisition: D. Giakoustidis, A.A. Gargavanis, N. for the management of post-transplant hepatocellular carcinoma
Salveridis, E. Cholongitas, E. Sinakos recurrence. J Hepatol 2013;59:3-5.
Data interpretation: D. Giakoustidis, A.A. Gargavanis, 7. Mazzola A, Costantino A, Petta S, Bartolotta TV, Raineri M, Sacco
N. Salveridis, E. Cholongitas, E. Sinakos, K. R, Brancatelli G, Cammà C, Cabibbo G. Recurrence of hepatocellular
Papapolychroniadis, V. Papanikolaou carcinoma after liver transplantation: an update. Future Oncol
Manuscript preparation: D. Giakoustidis, A.A. 2015;11:2923-36.
Gargavanis, N. Salveridis, E. Cholongitas, E. Sinakos 8. Zavaglia C, Airoldi A, Mancuso A, Vangeli M, Viganò R, Cordone
Manuscript editing: D. Giakoustidis G, Gentiluomo M, Belli LS. Adverse events affect sorafenib
Manuscript review: K. Papapolychroniadis, V. efficacy in patients with recurrent hepatocellular carcinoma after
Papanikolaou liver transplantation: experience at a single center and review of the
literature. Eur J Gastroenterol Hepatol 2013;25:180-6.
Financial support and sponsorship 9. Seong J, Koom WS, Park HC. Radiotherapy for painful bone
metastases from hepatocellular carcinoma. Liver Int 2005;25:261-5.
None. 10. He J, Zeng ZC, Fan J, Zhou J, Sun J, Chen B, Yang P, Wang BL,
Zhang BH, Zhang JY. Clinical features and prognostic factors in
Conflicts of interest patients with bone metastases from hepatocellular carcinoma after
There are no conflicts of interest. liver transplantation. BMC Cancer 2011;11:492.

208 Hepatoma Research ¦ Volume 3 ¦ September 20, 2017